Non-Muscle Invasive Bladder Neoplasms: all 273 studies

Page 3 of 3. Open to participants first (117), then studies with results posted, then the rest; newest registration first within each.

• Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder CancerStatus unknownNCT04859751Phase 3
• Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBCCompletedNCT04819399Phase 1
• Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG VaccineStatus unknownNCT04799847Phase 1/2
• Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT04738630Phase 2
• Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder CancerCompletedNCT04726735
• Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological MarkersCompletedNCT04723121Not applicable
• The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder CancerStatus unknownNCT04671407Phase 2
• Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder CancerStatus unknownNCT04664816Not applicable
• Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder CancerStatus unknownNCT04644835Not applicable
• The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and ProgressionCompletedNCT04617743
• Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory CultureWithdrawnNCT04583553
• Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG TherapyCompletedNCT04498702Phase 2
• Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) PatientsStatus unknownNCT04490993Phase 3
• Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinActive, not recruitingNCT04452591Phase 3
• Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC PatientsTerminatedNCT04412070
• Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCompletedNCT04387461Phase 2
• Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer PreventionActive, not recruitingNCT04375813Phase 2
• Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder CancerCompletedNCT04319263Not applicable
• Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective StudyCompletedNCT04194112Not applicable
• Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG TreatmentActive, not recruitingNCT04179162Phase 1/2
• Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)Active, not recruitingNCT04134000Phase 1
• Thulium Fiber Laser En-bloc Resection vs Conventional Transurethral Resection of Non-muscle-invasive Bladder CancerCompletedNCT04110483Not applicable
• A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102WithdrawnNCT04109092Phase 1
• Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer MonitorActive, not recruitingNCT04100733Not applicable
• A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)WithdrawnNCT04089163Phase 1
• Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionWithdrawnNCT04040725Phase 2
• Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as ProphylaxisStatus unknownNCT03982797Phase 2
• Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT03950362Phase 2
• A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk TumorsCompletedNCT03914794Phase 2
• A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder CancerCompletedNCT03854721Phase 1
• Continuous Bladder Irrigation Following Transurethral Resection of Bladder TumorsWithdrawnNCT03839472Not applicable
• Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer PatientsActive, not recruitingNCT03799835Phase 3
• Efficacy of Durvalumab in Non-muscle-invasive Bladder CancerStatus unknownNCT03759496Phase 2
• Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG TreatmentCompletedNCT03672240Phase 1/2
• A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)CompletedNCT03664258
• The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II StudyStatus unknownNCT03597087Not applicable
• The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological CorrelationCompletedNCT03591367Not applicable
• A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder CancerStatus unknownNCT03560479Phase 1/2
• Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder CancerActive, not recruitingNCT03528694Phase 3
• Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)Status unknownNCT03421236Phase 1
• Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.TerminatedNCT03335059Phase 3
• Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2
• Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder CancerWithdrawnNCT03298958Phase 3
• "En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized StudyStatus unknownNCT03221062Phase 4
• Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®CompletedNCT03191578Phase 1
• Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology ResidentStatus unknownNCT03148158
• A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)Status unknownNCT03121768
• Evaluation of a Patient-Reported Symptom Index for NMIBCCompletedNCT03091764
• Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) PatientsCompletedNCT03053635Phase 1
• Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?Status unknownNCT03038321Phase 4
• QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder CancerActive, not recruitingNCT03022825Phase 2/3
• Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBCTerminatedNCT02982395Phase 3
• Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder CancerCompletedNCT02969109
• Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder CancerActive, not recruitingNCT02948543Phase 3
• Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBCStatus unknownNCT02895620Not applicable
• Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral ResectionCompletedNCT02852564Phase 1
• A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder CancerCompletedNCT02753309Early Phase 1
• The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder CancerCompletedNCT02716623Not applicable
• Sexual Function in Patients Suspected of Non-muscle Invasive Bladder CancerCompletedNCT02381912
• VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerCompletedNCT02371447Phase 1/2
• Celecoxib for the Treatment of Non-muscle Invasive Bladder CancerCompletedNCT02343614Phase 2
• Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot StudyCompletedNCT02298998
• Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder CancerCompletedNCT02214602Phase 4
• A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder CancerActive, not recruitingNCT02138734Phase 1/2
• Therapeutic Instillation of MistletoeTerminatedNCT02106572Phase 3
• Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder CancerCompletedNCT02075060Not applicable
• A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)WithdrawnNCT01799499Not applicable
• Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder CancerCompletedNCT01731652Phase 2
• BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) PatientsCompletedNCT01498172Phase 1
• Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder CancerCompletedNCT01458847Phase 1
• A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)TerminatedNCT01314664
• Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder CancerCompletedNCT01149174Phase 3
• Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band ImagingCompletedNCT01004211Not applicable

← Non-Muscle Invasive Bladder Neoplasms overview